Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180146 | 1.00 | GSR (0.46) | GSRRNPEPCPB2GABRR1FOLH1 | |
| SCHEMBL4182311 | 0.95 | GABRR1 (0.41) | GSRRNPEPCPB2GABRR1GRIK1 | |
| SCHEMBL4182315 | 0.95 | GABRR1 (0.41) | GSRRNPEPCPB2GABRR1GRIK1 | |
| SCHEMBL4182307 | 0.95 | GABRR1 (0.41) | GSRRNPEPCPB2GABRR1GRIK1 | |
| SCHEMBL1886100 | 0.86 | GSR (0.43) | GSRRNPEPCPB2FOLH1GRIK1 | |
| SCHEMBL1886103 | 0.86 | GSR (0.43) | GSRRNPEPCPB2FOLH1GRIK1 | |
| SCHEMBL4299915 | 0.85 | GSR (0.48) | GSRRNPEPCPB2GABRR1FOLH1 | |
| SCHEMBL4299640 | 0.85 | GSR (0.48) | GSRRNPEPCPB2GABRR1FOLH1 | |
| SCHEMBL32679719 | 0.85 | GSR (0.42) | GSRRNPEPCPB2FOLH1GRIK1 | |
| SCHEMBL32679720 | 0.85 | GSR (0.42) | GSRRNPEPCPB2FOLH1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186853-A1 | COMPOSITIONS COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU RUEY J | 2009-07-23 | — | — | US | claimed |
| EP-1865953-A4 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU RUEY J (US) | 2008-04-30 | — | — | EP | claimed |
| EP-1865953-A2 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | Yu, Ruey J., Dr. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006101940-A2 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU, RUEY, J. (US) | 2006-09-28 | — | — | WO | claimed |
| US-20060211754-A1 | Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof | YU RUEY J | 2006-09-21 | — | — | US | claimed |
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AVANTOR PERFORMANCE MATERIALS, LLC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20110281939-A1 | POLYNUCLEOTIDE APTAMER-BASED CROSS-LINKED MATERIALS AND USES THEREOF | SMARTCELLS, INC. | 2011-11-17 | — | — | US | disclosed |
| US-20090186853-A1 | COMPOSITIONS COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU RUEY J | 2009-07-23 | — | — | US | disclosed |
| EP-1865953-A4 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU RUEY J (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1865953-A2 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | Yu, Ruey J., Dr. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006101940-A2 | COMPOSITION COMPRISING N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINOCARBOHYDRATES AND DERIVATIVES THEREOF | YU, RUEY, J. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060211754-A1 | Compositions comprising N-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof | YU RUEY J | 2006-09-21 | — | — | US | disclosed |
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AADAT, KYNU, PNISR | GSR 2191/4885RNPEP 75/4885CPB2 689/4885 |
| US-20110281939-A1 | POLYNUCLEOTIDE APTAMER-BASED CROSS-LINKED MATERIALS AND USES THEREOF | PNKP, ADAR, NCL | GSR 3987/4885RNPEP 596/4885CPB2 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.